0001193125-23-193453.txt : 20230725 0001193125-23-193453.hdr.sgml : 20230725 20230725161905 ACCESSION NUMBER: 0001193125-23-193453 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230725 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20230725 DATE AS OF CHANGE: 20230725 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UroGen Pharma Ltd. CENTRAL INDEX KEY: 0001668243 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38079 FILM NUMBER: 231108767 BUSINESS ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 BUSINESS PHONE: 972 9 770 7601 MAIL ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 8-K 1 d480915d8k.htm 8-K 8-K
false 0001668243 0001668243 2023-07-25 2023-07-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 25, 2023

 

 

UROGEN PHARMA LTD.

(Exact name of registrant as specified in its charter)

 

 

 

Israel   001-38079   98-1460746
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

400 Alexander Park Drive, 4th Floor

Princeton, New Jersey

  08540
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: +1 (646) 768-9780

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Ordinary Shares, par value NIS0.01 per share   URGN   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d)

On July 25, 2023, the board of directors (the “Board”) of UroGen Pharma Ltd., an Israeli company (the “Company”), at the recommendation of the Nominating and Corporate Governance Committee, increased the size of the Board from eight to nine directors, appointed James A. Robinson Jr. to fill the vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders, and also appointed Mr. Robinson to the Compliance Committee of the Board.

In accordance with the Company’s 2019 Officers’ Compensation Policy, Mr. Robinson received an initial option grant to purchase 20,000 ordinary shares of the Company (“Ordinary Shares”). The option vests in equal quarterly installments for 12 quarters. Mr. Robinson is also eligible to receive an annual retainer of $40,000 for his service on the Board, an additional annual retainer of $5,000 for his service on the Compliance Committee of the Board, and an annual option grant to purchase 10,000 Ordinary Shares on the date of each annual shareholder meeting of the Company.

The Company will enter into its standard form of indemnity agreement for directors and officers with Mr. Robinson, a copy of which is filed as Exhibit 10.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 25, 2023   UROGEN PHARMA LTD.
    By:  

/s/ Don Kim

      Don Kim
      Chief Financial Officer
EX-101.SCH 2 urgn-20230725.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 urgn-20230725_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 urgn-20230725_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Jul. 25, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001668243
Document Type 8-K
Document Period End Date Jul. 25, 2023
Entity Registrant Name UROGEN PHARMA LTD.
Entity Incorporation State Country Code L3
Entity File Number 001-38079
Entity Tax Identification Number 98-1460746
Entity Address, Address Line One 400 Alexander Park Drive
Entity Address, Address Line Two 4th Floor
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code (646)
Local Phone Number 768-9780
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Ordinary Shares, par value NIS0.01 per share
Trading Symbol URGN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 d480915d8k_htm.xml IDEA: XBRL DOCUMENT 0001668243 2023-07-25 2023-07-25 false 0001668243 8-K 2023-07-25 UROGEN PHARMA LTD. L3 001-38079 98-1460746 400 Alexander Park Drive 4th Floor Princeton NJ 08540 (646) 768-9780 false false false false Ordinary Shares, par value NIS0.01 per share URGN NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( &*"^58'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !B@OE6;=VEPN\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O31%Q=#E9<,G!<&!XEM(;EM8DX;DI-VWMZU;A^@'\#%W__SN M=W"-B=)T"5]2%S&1PWPS^#9D:>**'8BB!,CF@%[GHC9' MO4<0G-^!1])6DX8)6,2%R%1CC30)-77IC+=FP_/3Z_SNH4+ MF70P./[*3M(IXHI=)K_5Z\WVD2G!15WP^T+<;@67U8/D]&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !B@OE6*K8PH6T$ X$0 & 'AL+W=OFF04;%M/L0J0L M@3LK(6.JH"G79I9*1L-B4!R9CF5Y9DQY8@S[Q6^^'/9%KB*>,%^2+(]C*M]O M6"2V \,V/GZ8\?5&Z1_,83^E:S9GZB7U);3,2B7D,4LR+A(BV6I@C.SK&Z>C M!Q0]_N)LFQU<$SV5I1"ONC$)!X:EB5C$ J4E*'R]L3&+(JT$'#_VHD;U3#WP M\/I#_;Z8/$QF23,V%M%W'JK-P.@9)&0KFD=J)K9?V'Y"!6 @HJSX)-NRKVL9 M),@S)>+]8""(>5)^T]T^$(<#.D<&./L!3L%=/JB@O*6*#OM2;(G4O4%-7Q13 M+48#'$_TJLR5A+LB>3I%QMB%K?5/ 0W=4,]H(W MI:!S1/!K'ET0IW-&',NY_'FX"6P5H%,!.H7>Y1&]L7ACDOPS6F9*PA+^VT14 M*KC-"CJOK[.4!FQ@0.)F3+XQ8_CK+[9G_8'P759\EYCZ< 31"XL(WD=TW42' MCU_1*&,(AUMQN*C.?NW&0")I!&L8LAWYQMZ;B' ER[)LS^LY+K9\G0JK@XI5 M^;5X3UD3"SZ\=_X-@? J".\T")])+G2>AP1V2R,/KE1E=UMZ=RNT[BG+-F-K MKA,<&*1N1Q<7N!P/4JN-XI<),D$#(5LG $,E<0 M.3(6.20:Y)L(&VEQX4U;U">&RK M]E+K%*(%W9%)"/G&5SPH@W:\^K/#&Y]6J>?U:]%K):OMW<*_^']DDRW(@:P7$95L! M#U[V<7.>LR"7>OO9SI(LN(H:MU^+R+,,>0)'3#+?4'"7,Y)22=YHE,,>FLRM M"\LF*@ %J,&0ARE-&L\G+8)'T\T\ M. ?K_Q2>J'YB1B*V B'KH@NZLCRFEPTETN)HO!0*#MK%Y891V JZ ]Q?":$^ M&OJT7?U9,OP/4$L#!!0 ( &*"^5:?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8 M^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L M*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @: ML!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI M\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6; M_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2 M]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$= MV_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M> M;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:* M(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D M>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8 MJ;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( &*"^5:7BKL

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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d480915d8k.htm urgn-20230725.xsd urgn-20230725_lab.xml urgn-20230725_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d480915d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "d480915d8k.htm" ] }, "labelLink": { "local": [ "urgn-20230725_lab.xml" ] }, "presentationLink": { "local": [ "urgn-20230725_pre.xml" ] }, "schema": { "local": [ "urgn-20230725.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "urgn", "nsuri": "http://www.urogen.com/20230725", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d480915d8k.htm", "contextRef": "duration_2023-07-25_to_2023-07-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d480915d8k.htm", "contextRef": "duration_2023-07-25_to_2023-07-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.urogen.com//20230725/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001193125-23-193453-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-193453-xbrl.zip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